Barnett & Company’s Genmab GMAB Stock Holding History

Barnett & Company’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-145	Closed	-$3K	–	390
2019 Q4	$3K	Buy	+145	New	+$3.16K	﹤0.01%	416

Other funds holding GMAB

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Barnett & Company's GMAB Position: Q1 2020 in Review

Barnett & Company sold out of Genmab (GMAB) in Q1 2020, closing a stake of 145 shares — an estimated $3K sold.

Barnett & Company first reported a position in GMAB in Q4 2019 and held it in 1 quarter. The position peaked at $3K in Q4 2019. 142 funds tracked by Wall St. Rank hold GMAB as of Q1 2020.

Barnett & Company reported no remaining Genmab position as of Q1 2020 after selling out during the quarter.
Barnett & Company sold 145 Genmab shares in Q1 2020, an estimated $3K.
Barnett & Company first reported a position in Genmab in Q4 2019 and held it in 1 quarter.
Barnett & Company's Genmab position peaked at $3K in Q4 2019.
142 funds tracked by Wall St. Rank held Genmab as of Q1 2020.

Based on Barnett & Company's 13F filing for Q1 2020, filed 23 Apr 2020.